Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis
Nikkia Zarabian, Mina Farah, Joseph Zahn, Adam Friedman · 2026
Read Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis by Nikkia Zarabian, Mina Farah, Joseph Zahn, Adam Friedman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13348051.txt.
Description
Nikkia Zarabian and co-authors told in 2026 of a severe psoriasis flare after tralokinumab therapy for atopic dermatitis. This adverse event is rare and poorly grasped. Tralokinumab blocks interleukin-13. It is approved for moderate to severe eczema in patients aged twelve and up. Trials showed a largely kind safety profile.
The case spells out checks and care for a patient whose skin illness shifted sharply after starting the biologic. It raises asks about how blocking one inflammation path can unmask another. Usual side effects are upper airway infections, eye inflammation, and jab-site reactions. This flare stands out from that list. The report urges clinicians to watch for paradox skin reactions when targeted eczema drugs shift immune balance.
Catalog record
| CREATOR | Nikkia Zarabian, Mina Farah, Joseph Zahn, Adam Friedman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |